Editorials

Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions

Paul E Langton, Graeme J Hankey and John W Eikelboom

Med J Aust 2004; 181 (10): 524-525.

Article
Authors
References

We need processes in place to follow up suspicions about serious adverse events

Paul E Langton, BSc, MB BS (Hons), FRACP, Cardiologist, and Clinical Lecturer, School of Medicine and Pharmacology, University of Western Australia1

Graeme J Hankey, MD, FRACP, FRCP, Neurologist, and Clinical Professor, School of Medicine and Pharmacology, University of Western Australia2

John W Eikelboom, MB BS, MSc, FRACP, Haematologist, and Clinical Lecturer, School of Medicine and Pharmacology, University of Western Australia3

1 Hollywood Private Hospital, Perth, WA.

2 Royal Perth Hospital, Perth, WA.

Article References:

Reference Text:

Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528.

Reference Order:

PubMed ID:

11087881

Reference Link:

Reference Text:

Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoarthritic and rheumatoid arthritis. The CLASS study: a randomised controlled trial. JAMA 2000; 284: 1247-1255.

Reference Order:

PubMed ID:

10979111

Reference Link:

i1085791

Reference Text:

Department of Health and Ageing. Expenditure and prescriptions twelve months to 30 June 2004. Available at: www.health.gov.au/internet/wcms/publishing.nsf/Content/health-pbs-general-pubs-pbbexp-jun04.htm (accessed Oct 2004).

Reference Order:

PubMed ID:

Reference Link:

i1085793

Reference Text:

Department of Health and Ageing. Therapeutic Goods Administration. Consumer level recall of arthritis drug. Media release. Available at: www.tga.gov.au/media/2004/040930_vioxx.htm (accessed Oct 2004).

Reference Order:

PubMed ID:

Reference Link:

i1085795

Reference Text:

Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomised, controlled trial. Ann Intern Med 2003; 139: 539-546.

Reference Order:

PubMed ID:

14530224

Reference Link:

i1085797

Reference Text:

Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.

Reference Order:

PubMed ID:

11509060

Reference Link:

i1085799

Reference Text:

Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-2073.

Reference Order:

PubMed ID:

15096449

Reference Link:

i1085801

Reference Text:

Topol EJ, Falk GW. A coxib a day won’t keep the doctor away. Lancet 2004; 364: 639-640.

Reference Order:

PubMed ID:

15325809

Reference Link:

i1085803

Reference Text:

Hankey GJ, Eikelboom JW. Cyclooxygenase-2 inhibitors. Are they really atherothrombotic, and if not, why not? Stroke 2003; 34: 2736-2740.

Reference Order:

PubMed ID:

14576372

Reference Link:

i1085805

Reference Text:

Fitzgerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2: 879-890.

Reference Order:

PubMed ID:

14668809

Reference Link:

i1085807

Reference Text:

Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-1710.

Reference Order:

PubMed ID:

15470192

Reference Link:

i1085809

Reference Text:

Bogaty P, Brophy JM, Noel M, et al. Impact of prolonged cyclo-oxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein. A randomised placebo-controlled study. Circulation 2004; 110: 934-939.

Reference Order:

PubMed ID:

15302800

Reference Link:

i1085811

Reference Text:

Farkouh M, Kirshner H, Harrington RA, et al, on behalf of the TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-684.

Reference Order:

PubMed ID:

15325832

Reference Link:

i1085813

Reference Text:

Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481-1492.

Reference Order:

PubMed ID:

12830070

Reference Link:

i1085815

Reference Text:

Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004; 63: 901-907.

Reference Order:

PubMed ID:

15020311

Reference Link:

i1085817

Reference Text:

Pollack A. A new trial of celebrex, and questions on its timing. The New York Times 2004; 19 Oct. Available at: www.nytimes.com/2004/10/19/business/19drug.html (accessed Oct 2004).

Reference Order:

PubMed ID:

Reference Link:

i1085819

The full contents of this page are only available to subscribers.

Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions

Subscribe to the MJA

ARTICLES

TOPICS

MY ACCOUNT

ADVERTISE

Search form

Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions

Log in to keep reading

Not a subscriber?

Subscribe to the MJA

ARTICLES

TOPICS

MY ACCOUNT

ADVERTISE

MJA